| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/100-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | FOXO1 |
| Entrez GeneID | 2308; |
| WB Predicted band size | 78-82 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Peptide sequence around aa.254~258 (A-A-S-M-D) derived from Human FKHR/FOXO1A. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于 **FKHR (FOXO1. Ab-256)** 抗体的示例参考文献(内容为模拟，实际文献需通过数据库查询)：
---
1. **文献名称**: *"FOXO1 phosphorylation by AKT promotes its nuclear exclusion and transcriptional inactivation in prostate cancer cells"*
**作者**: Brunet, A. et al.
**摘要**: 研究通过使用 FKHR (Ab-256) 抗体进行免疫印迹和免疫荧光实验，揭示了 AKT 介导的 FOXO1 磷酸化导致其核排斥，从而抑制促凋亡基因的表达，促进前列腺癌细胞存活。
2. **文献名称**: *"Regulation of glucose metabolism by FOXO1 in hepatic cells"*
**作者**: Nakae, J. et al.
**摘要**: 利用 FKHR (Ab-256) 抗体检测 FOXO1 在肝细胞中的表达及定位，发现胰岛素信号通过 PI3K/AKT 通路调控 FOXO1 的核质穿梭，影响糖异生关键酶的表达。
3. **文献名称**: *"FOXO1 interacts with β-catenin to regulate epithelial-mesenchymal transition in breast cancer"*
**作者**: Xie, L. et al.
**摘要**: 通过免疫共沉淀(使用 Ab-256 抗体)和 ChIP 实验，证明 FOXO1 与 β-catenin 相互作用，抑制 EMT 进程，从而降低乳腺癌转移潜能。
4. **文献名称**: *"Antibody validation and functional analysis of FOXO1 isoforms using Ab-256 in neurodegenerative models"*
**作者**: Wang, Y. et al.
**摘要**: 验证了 Ab-256 抗体对 FOXO1 不同亚型的特异性，并应用于阿尔茨海默病模型，发现 FOXO1 的异常核积累与神经元凋亡相关。
---
**注**：以上为示例，实际文献需通过 **PubMed、Google Scholar** 或抗体供应商(如 CST、Abcam)官网提供的引用列表查询。若 Ab-256 为某公司特定产品编号，建议直接参考其产品手册或技术支持提供的文献。
The FKHR (Ab-256) antibody is a tool used to detect the Forkhead Box O1 (FOXO1) protein, a member of the FOXO transcription factor family. FOXO1. formerly known as FKHR (Forkhead in Rhabdomyosarcoma), regulates critical cellular processes including apoptosis, cell cycle arrest, oxidative stress resistance, and glucose metabolism. Dysregulation of FOXO1 is implicated in cancer, diabetes, and aging-related disorders. The Ab-256 antibody specifically targets FOXO1. enabling researchers to study its expression, localization, and post-translational modifications (e.g., phosphorylation) in various biological contexts.
FOXO1 activity is tightly controlled by the PI3K-AKT signaling pathway. AKT-mediated phosphorylation of FOXO1 promotes its nuclear exclusion and inactivation, linking cellular signaling to transcriptional regulation. The FKHR (Ab-256) antibody is widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate FOXO1’s role in diseases such as diabetes (via insulin signaling) and cancer (via tumor suppression or context-dependent oncogenic effects).
This antibody has been valuable in elucidating FOXO1’s dual role in health and disease, particularly its interplay with metabolic pathways and stress responses. Its specificity and reliability make it a key reagent for studies exploring FOXO1 as a therapeutic target or biomarker in conditions like hepatocellular carcinoma, type 2 diabetes, and neurodegenerative disorders.
×
